SG11201705695QA - Differentiation of macrophages from pluripotent stem cells - Google Patents

Differentiation of macrophages from pluripotent stem cells

Info

Publication number
SG11201705695QA
SG11201705695QA SG11201705695QA SG11201705695QA SG11201705695QA SG 11201705695Q A SG11201705695Q A SG 11201705695QA SG 11201705695Q A SG11201705695Q A SG 11201705695QA SG 11201705695Q A SG11201705695Q A SG 11201705695QA SG 11201705695Q A SG11201705695Q A SG 11201705695QA
Authority
SG
Singapore
Prior art keywords
macrophages
differentiation
stem cells
pluripotent stem
pluripotent
Prior art date
Application number
SG11201705695QA
Inventor
Hwei-In Shawn Lim
Tara Huber
Florent Ginhoux
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201705695QA publication Critical patent/SG11201705695QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
SG11201705695QA 2015-01-16 2016-01-18 Differentiation of macrophages from pluripotent stem cells SG11201705695QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201500366V 2015-01-16
PCT/SG2016/050018 WO2016114723A1 (en) 2015-01-16 2016-01-18 Differentiation of macrophages from pluripotent stem cells

Publications (1)

Publication Number Publication Date
SG11201705695QA true SG11201705695QA (en) 2017-08-30

Family

ID=56406143

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705695QA SG11201705695QA (en) 2015-01-16 2016-01-18 Differentiation of macrophages from pluripotent stem cells

Country Status (6)

Country Link
US (2) US10724003B2 (en)
EP (1) EP3245289B1 (en)
JP (1) JP6774952B2 (en)
CN (1) CN107208062B (en)
SG (1) SG11201705695QA (en)
WO (1) WO2016114723A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
CN107208062B (en) * 2015-01-16 2021-03-09 新加坡科技研究局 Differentiation of macrophages from pluripotent stem cells
US11285174B2 (en) 2016-09-19 2022-03-29 The University Court Of The University Of Edinburgh Macrophage-based therapy for use in the treatment of liver injury
EP3399027A1 (en) 2017-05-04 2018-11-07 Medizinische Hochschule Hannover Stem-cell derived myeloid cells, generation and use thereof
US11629331B2 (en) 2017-07-19 2023-04-18 Seoul National University R & Db Foundation Method of differentiation of human induced pluripotent stem cell to dermal papilla precursor cell and use thereof
WO2019017691A2 (en) * 2017-07-19 2019-01-24 서울대학교 산학협력단 Method of differentiation of human induced pluripotent stem cell to dermal papilla precursor cell and use thereof
CN107807234A (en) * 2017-10-30 2018-03-16 柏基香 A kind of method for detecting intracerebral microglia phagocytic activity
CN107630000B (en) * 2017-11-06 2021-07-13 中国农业大学 Kit for separating and culturing peripheral blood-derived macrophages of livestock
US20200131476A1 (en) * 2017-12-11 2020-04-30 Korea Center For Disease Control And Prevention Differentiation Of Immunocytes Using Pluripotent Stem Cells
JP2021510527A (en) * 2018-01-18 2021-04-30 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ Methods for Differentiation of Human Pluripotent Stem Cell Lines in Suspension Culture
CN108300695B (en) * 2018-02-07 2021-08-06 清华大学 Method for differentiating human pluripotent stem cells into hematopoietic stem cells and culture additive
CA3109546A1 (en) * 2018-09-07 2020-03-12 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
CN109082411B (en) * 2018-09-07 2022-06-07 赛元生物科技(杭州)有限公司 Method for obtaining phagocytic macrophage by differentiation of pluripotent stem cells
AU2019347876A1 (en) * 2018-09-28 2021-05-13 Memorial Sloan-Kettering Cancer Center Stem cell-derived human microglial cells, methods of making and methods of use
CN109266618B (en) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 Macrophage capable of targeting tumor cells and preparation method thereof
CN113924362A (en) * 2019-03-29 2022-01-11 新加坡科技研究局 Microglial-rich brain organoids
CA3227202A1 (en) * 2021-08-19 2023-02-23 Cedars-Sinai Medical Center Ipsc-derived immune cells in prophylaxis and treatment of age-associated and neurodegenerative diseases
WO2024034656A1 (en) * 2022-08-09 2024-02-15 Ａｇｃ株式会社 METHOD FOR PRODUCING PROLIFERATIVE MACROPHAGE-LIKE CELLS (pMAC)
CN115433715B (en) * 2022-08-15 2023-04-14 呈诺再生医学科技(北京)有限公司 Culture medium and method for inducing iPSC differentiation to obtain macrophages and application of culture medium
WO2024054769A1 (en) * 2022-09-07 2024-03-14 Deverra Therapeutics Inc. Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells
KR20240054468A (en) * 2022-10-18 2024-04-26 의료법인 성광의료재단 Medium composition for inducing differentiation from pluripotent stem cells to macrophages and a differentiation method using the same
CN116731967B (en) * 2023-08-16 2023-11-17 南京大学 Method for preparing macrophage from multipotent stem cells by induced differentiation
CN116987667B (en) * 2023-09-26 2024-01-09 天海元祺生物科技(天津)有限公司 Method for differentiating pluripotent stem cells into macrophages or neutrophils
CN117448269A (en) * 2023-10-25 2024-01-26 中国科学院香港创新研究院再生医学与健康创新中心有限公司 Method for inducing human pluripotent stem cells to rapidly differentiate into macrophages and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002025A1 (en) * 1988-11-02 1990-05-02 Geary W. Collins Continuous mammalian cell lines having monocyte-macrophage characteristics and their establishment in vitro
CN102008503B (en) * 2001-12-07 2018-10-09 阿斯特利亚斯生物治疗股份公司 The hematopoietic cell of derived from human embryonic stem
WO2010094734A2 (en) * 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
CN102388130B (en) 2009-02-27 2014-08-27 细胞动力国际有限公司 Differentiation of pluripotent cells
CN103179981B (en) 2010-07-30 2017-02-08 Ac免疫有限公司 Safe and functional humanized antibodies
WO2014012933A1 (en) * 2012-07-16 2014-01-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the generation of non-transformed macrophage cell lines
US10266807B2 (en) * 2013-04-03 2019-04-23 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
US10081792B2 (en) * 2014-12-31 2018-09-25 Wisconsin Alumni Research Foundation Derivation of human microglia from pluripotent stem cells
CN107208062B (en) * 2015-01-16 2021-03-09 新加坡科技研究局 Differentiation of macrophages from pluripotent stem cells
WO2016127259A1 (en) * 2015-02-11 2016-08-18 The Hospital For Sick Children Alveolar-like macrophages and method of generating same

Also Published As

Publication number Publication date
WO2016114723A1 (en) 2016-07-21
EP3245289A4 (en) 2018-06-27
JP2018503375A (en) 2018-02-08
US11618886B2 (en) 2023-04-04
CN107208062B (en) 2021-03-09
US20200399601A1 (en) 2020-12-24
EP3245289B1 (en) 2021-07-07
EP3245289A1 (en) 2017-11-22
US10724003B2 (en) 2020-07-28
CN107208062A (en) 2017-09-26
US20180010096A1 (en) 2018-01-11
JP6774952B2 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
SG11201705695QA (en) Differentiation of macrophages from pluripotent stem cells
HK1257460A1 (en) Genetic engineering of macrophages for immunotherapy
IL287033A (en) Nuclease-mediated regulation of gene expression
SG11201801549VA (en) Pluripotent stem cell production system
SG11201708359TA (en) Generation of functional cells from stem cells
IL250689A0 (en) Resetting pluripotent stem cells
IL250132A0 (en) Method for inducing t cells for immunocytotheraphy from pluripotent stem cells
ZA201704868B (en) Suspension culturing of pluripotent stem cells
GB201511567D0 (en) Superhard constructions & methods of making same
SG11201705750WA (en) Method for inducing differentiation of corneal epithelial cells from pluripotent stem cells
EP3286301A4 (en) Generation of muscle-lineage cells from stem cells
SG11201609091YA (en) Method for assessing state of differentiation of cells
SG11201701655YA (en) Differentiation of hepatocyte-like cells from stem cells
IL263557B (en) Differentiation of pluripotent stem cells into corneal cells
GB201518282D0 (en) Superhard constructions & methods of making same
ZA201708773B (en) Agent for promoting migration of pluripotent stem cells
GB201523085D0 (en) Superhard constructions & methods of making same
GB201504576D0 (en) Superhard constructions & methods of making same
SG11201703600YA (en) Method of distinguishing mesenchymal stem cells
HK1252554A1 (en) Pluripotent stem cell production system
GB201420853D0 (en) Methods for differentiation of primate pluripotent stem cells
GB201513868D0 (en) In Vitro production of expanded potential stem cells
GB201513869D0 (en) In vitro production of expanded potential stem cells
GB201415368D0 (en) Resetting pluripotent stem cells
GB201420385D0 (en) In vitro production of expanded potential stem cells